Additional SNPs improve the performance of a polygenic hazard score for prostate cancer

التفاصيل البيبلوغرافية
العنوان: Additional SNPs improve the performance of a polygenic hazard score for prostate cancer
المؤلفون: Azad Razack, Hermann Brenner, Eleanor I Walsh, Susan L. Neuhausen, David E. Neal, Alicja Wolk, Ole A. Andreassen, Catharine M L West, Jong Y. Park, Anders M. Dale, Catherine M. Tangen, Johanna Schleutker, Wei Zheng, Richard M. Martin, Sue A. Ingles, Barry Rossenstein, Ana Vega, Esther M. John, Apcb BioResource, Karina Dalsgaard Sørensen, Wesley K. Thompson, Stella Koutros, Christopher A. Haiman, Freddie C. Hamdy, Athene Lane, Lisa F. Newcomb, Chun Chieh Fan, Børge G. Nordestgaard, Nawaid Usmani, Sonja I. Berndt, Janet L. Stanford, Emma L Turner, Cezary Cybulski, Robert J. Hamilton, Artitaya Lophatananon, Kenneth Muir, Manolis Kogevinas, Nora Pashayan, Olivier Cussenot, Henrik Grönberg, Adam S. Kibel, Robert J. MacInnis, Radka Kaneva, Ruth C. Travis, Roshan Karunamuni, Christopher J. Logothetis, Canary Pass Investigators, Rosalind A. Eeles, Christiane Maier, Jenny L Donovan, Minh-Phuong Huynh-Le, Ian G. Mills, Lorelei A. Mucci, Sune F. Nielsen, Tyler M. Seibert, Manuela Gago-Dominguez, Eli Marie Grindedal, Paul A. Townsend, Zsofia Kote-Jarai, Demetrius Albanes, Fredrik Wiklund, Manuel R. Teixeira, Frank Claessens, Kathryn L. Penney, Monique J Roobol, Marija Gamulin, Jyotsna Batra
بيانات النشر: Cold Spring Harbor Laboratory, 2020.
سنة النشر: 2020
مصطلحات موضوعية: Oncology, medicine.medical_specialty, Training set, medicine.diagnostic_test, business.industry, Proportional hazards model, Hazard ratio, Single-nucleotide polymorphism, medicine.disease, Elevated PSA, Prostate cancer, Increased risk, Internal medicine, Biopsy, Medicine, business
الوصف: BackgroundPolygenic hazard scores (PHS) can identify individuals with increased risk of prostate cancer. We estimated the benefit of additional SNPs on performance of a previously validated PHS (PHS46).Materials and Method180 SNPs, shown to be previously associated with prostate cancer, were used to develop a PHS model in men with European ancestry. A machine-learning approach, LASSO-regularized Cox regression, was used to select SNPs and to estimate their coefficients in the training set (75,596 men). Performance of the resulting model was evaluated in the testing/validation set (6,411 men) with two metrics: (1) hazard ratios (HRs) and (2) positive predictive value (PPV) of prostate-specific antigen (PSA) testing. HRs were estimated between individuals with PHS in the top 5% to those in the middle 40% (HR95/50), top 20% to bottom 20% (HR80/20), and bottom 20% to middle 40% (HR20/50). PPV was calculated for the top 20% (PPV80) and top 5% (PPV95) of PHS as the fraction of individuals with elevated PSA that were diagnosed with clinically significant prostate cancer on biopsy.Results166 SNPs had non-zero coefficients in the Cox model (PHS166). All HR metrics showed significant improvements for PHS166 compared to PHS46: HR95/50 increased from 3.72 to 5.09, HR80/20 increased from 6.12 to 9.45, and HR20/50 decreased from 0.41 to 0.34. By contrast, no significant differences were observed in PPV of PSA testing for clinically significant prostate cancer.ConclusionIncorporating 120 additional SNPs (PHS166 vs PHS46) significantly improved HRs for prostate cancer, while PPV of PSA testing remained the same.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1faa945623ce40d958b7c0c160b2e538Test
https://doi.org/10.1101/2020.09.11.20188383Test
حقوق: OPEN
رقم الانضمام: edsair.doi...........1faa945623ce40d958b7c0c160b2e538
قاعدة البيانات: OpenAIRE